Clinical Study

Ea4151-A Randomized Phase III Trial Of Consolidation With Autologous Hematopoietic Cell Transplantation Followed By Maintenance Rituximab Vs. Maintenance Rituximab Alone For Patients With Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Com

Posted Date: Mar 4, 2020

  • Investigator: Tahir Latif
  • Specialties: Cancer, Lymphoma, Oncology
  • Type of Study: Drug

The primary goal of this study is to compare overall survival in MCL patients in MRD-negative first complete remission (CR) who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone (without auto-HCT)


To Be Eligible: Must Have Confirmed Mantle Cell Lymphoma, 18-70 Yrs Of Age, No Cns Involvement Of Cancer, 4+ Cycles Of Induction Therapy, Complete Or Partial Remission, Ecog 0-2, No Other Malignancy Within 3 Years


Mantle Cell Lymphoma, Mlc, Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.